
COORDINATOR
Prof. Dr. Anna LICATA, MD

COORDINATOR
Dr. Marina VILLANUEVA PAZ

COORDINATOR
Prof. Dr. Jane Grove

YOUNG INVESTIGATORS AFTERWORKS SERIES‘ COORDINATOR
Prof. Ann DALY
Monthly International Seminar Series on Liver Toxicity and Steatotic Liver Disease and different EASL studio topics for DHILI will be organised at a later stage.

As a proposal within our educational activities, we will be launching from January a series of talks on Liver Toxicity and Steatotic Liver Disease, ONCE monthly, given by international experts in the field. The session outline would be a talk of around 45 min with 15 min left for discussion. Conferences will be held on the 3rd Wednesday of each month at 16.30h (CET) starting from January 17th 2024.
These international seminar series are the result of an outstanding collaboration between the EASL DHILI Consortium (https://easldhiliconsortium.eu/) and the Halt-RONIN (UKRI-Horizon Europe) https://halt-ronin.com/
The objectives are:
- to improve collaboration between different group experts encompassing clinical investigators, researchers, basic scientists, industry partners and regulators.
- To foster scientific progress by disseminating the latest breakthroughs in research on hepatotoxicity and metabolic dysfunction-associated steatotic liver disease

Magnus Ingelman-Sundberg, PhD; BSc.Med is Professor of Molecular Toxicology and research group leader in Pharmacogenetics at the Department of Physiology and Pharmacology, Karolinska Institutet. He has more than 520 original papers and a h-factor of 101 (ISI/Clarivate) or 132 (Google Scholar). Assigned “Highly Cited Researcher” for 2014-2017 and 2021-2024 by Thomson & Reuters/Clarivate. His research focuses on genetics, polymorphism, regulation, function and toxicology of the hepatic ADME system with aims at understanding interindividual differences in drug response. Furthermore he develops novel hepatic in vitro systems for studying liver function, liver diseases and validation of hepatic drug targets. Summary The lecture will be focused on our development of a 3D liver spheroid system that closely mirrors the transcriptome, proteome, and metabolome of the corresponding donor liver. This model has proven highly effective in: i) predicting and understanding mechanisms behind drug-induced hepatotoxicity, ii) assessing the hepatic disposition and metabolite formation of low-clearance drugs, iii) elucidating the mechanisms of viral-induced hepatitis and the specific actions of viruses within the liver, iv) evaluating mechanisms of hepatocyte proliferation and v) understanding the processes by which a high-fat diet induces liver fibrosis and the molecular drivers of liver fibrosis degradation.